Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Desonide API Manufacturers & Suppliers
8 verified results
All Desonide data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 200+
All certificates
Employees: 50+
All certificates
Employees: 200+
All certificates
Employees: 400+
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Desonide | CAS No: 638-94-8 | GMP-certified suppliers
A medication that provides relief for inflammatory and itchy corticosteroid‑responsive skin conditions, supporting consistent dermatological formulation needs for North American therapeutic markets.
Therapeutic categories
Primary indications
- For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose
Product Snapshot
- Desonide is a topical small-molecule corticosteroid available in multiple cutaneous and ophthalmic formulations including creams, lotions, ointments, gels, solutions, and foams
- It is used for corticosteroid‑responsive inflammatory and pruritic dermatologic conditions
- It is approved in the US and Canada, with both approved and investigational statuses noted across formulations
Clinical Overview
Pharmacologically, desonide functions as a moderately potent corticosteroid intended for dermatologic use. Its therapeutic activity reflects anti‑inflammatory, antipruritic, and vasoconstrictive effects mediated through glucocorticoid receptor agonism. After topical administration, the drug binds cytosolic glucocorticoid receptors, and the resulting complex translocates to the nucleus to modulate gene transcription. A key downstream pathway involves induction of phospholipase A2 inhibitory proteins, or lipocortins, which limit the liberation of arachidonic acid from membrane phospholipids. This reduces the biosynthesis of prostaglandins and leukotrienes, thereby diminishing inflammatory mediator production at the site of application.
Systemic absorption is typically low when applied to intact skin, but uptake increases with occlusion, compromised epidermal barriers, large treatment areas, or prolonged use. Metabolic pathways are primarily hepatic, consistent with corticosteroid biotransformation, and the drug is known to interact with cytochrome P450 3A systems as both a substrate and inducer. Distribution and elimination parameters are influenced by the low systemic exposures achieved with proper topical use.
Safety considerations center on local corticosteroid effects such as skin atrophy, irritation, telangiectasia, and potential hypothalamic‑pituitary‑adrenal axis suppression when used extensively or under conditions that increase absorption. Use near the eyes requires caution due to the theoretical risk of elevated intraocular pressure or cataract formation reported with corticosteroids. Long‑term continuous application is generally avoided unless clinically justified.
Desonide is available in various topical formulations globally, including creams, lotions, gels, and ointments. For API procurement, sourcing should prioritize material identity verification, impurity profile control aligned with ICH expectations, and consistent potency to support formulation reproducibility and regulatory compliance.
Identification & chemistry
| Generic name | Desonide |
|---|---|
| Molecule type | Small molecule |
| CAS | 638-94-8 |
| UNII | J280872D1O |
| DrugBank ID | DB01260 |
Pharmacology
| Summary | Desonide is a topical corticosteroid that modulates inflammatory and pruritic responses by activating cytosolic glucocorticoid receptors and altering downstream gene transcription. Its activity is primarily attributed to induction of lipocortins, which inhibit phospholipase A2 and reduce production of prostaglandins and leukotrienes. The drug’s pharmacologic effect centers on suppressing key inflammatory pathways in corticosteroid‑responsive dermatologic conditions. |
|---|---|
| Mechanism of action | Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. |
| Pharmacodynamics | Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Glucocorticoid receptor | Humans | agonist |
ADME / PK
| Absorption | Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption. |
|---|
Formulation & handling
- Desonide is a small‑molecule corticosteroid formulated primarily for topical and ophthalmic use, relying on semi‑solid or liquid vehicles to address its low aqueous solubility.
- Its moderate lipophilicity (LogP ~1.9) supports incorporation into creams, ointments, lotions, and emulsions, with excipient selection focused on maintaining uniform dispersion and preventing crystallization.
- Being a solid steroidal API, it is generally stable but requires protection from excessive heat and light, with attention to oxidative stability in emulsified and solution‑based systems.
Regulatory status
| Lifecycle | Most U.S. patents for the API have already expired, with the final protection ending in 2028, indicating a late‑stage lifecycle. In the U.S. and Canada, the market is largely mature, with remaining exclusivity expected to conclude in the near term. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Desonide is supplied by numerous manufacturers and packagers, indicating that the original product’s role has diminished and the market is largely supported by established generic producers. Branded and generic formulations are available in the US and Canada, reflecting broad regional penetration. Most core patents have expired, with only later‑expiring formulation‑related patents remaining, supporting the presence of existing generics alongside limited protected presentations. |
|---|
Desonide is a type of Dermatics
Dermatics is a prominent subcategory within the pharmaceutical Active Pharmaceutical Ingredient (API) sector. It focuses on the development and production of APIs specifically designed for dermatological applications. These APIs play a crucial role in the formulation of various pharmaceutical products used in the treatment of skin disorders, including creams, ointments, gels, and lotions.
Dermatics APIs are meticulously developed to address specific dermatological conditions such as acne, psoriasis, eczema, fungal infections, and other related ailments. The APIs used in these formulations are carefully selected for their therapeutic efficacy, safety, and compatibility with the skin.
Manufacturers of Dermatics APIs employ rigorous quality control measures to ensure the purity, potency, and stability of their products. These APIs undergo extensive testing to meet stringent regulatory standards and pharmacopoeial guidelines. Additionally, the production processes adhere to Good Manufacturing Practices (GMP) to guarantee consistent quality and minimize the risk of contamination.
With the increasing demand for advanced dermatological treatments, Dermatics APIs are subject to continuous research and development. Newer APIs are being explored to enhance efficacy, minimize side effects, and improve patient compliance. The field of Dermatics APIs is characterized by innovation, as researchers strive to develop novel compounds and delivery systems that address unmet therapeutic needs.
In summary, Dermatics APIs are a vital component of pharmaceutical formulations used in the treatment of skin disorders. They undergo stringent quality control measures and are constantly evolving to provide effective and safe dermatological solutions.
Desonide (Dermatics), classified under Dermatological Agents
Dermatological agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the formulation of various skincare and dermatology products. These APIs are specifically designed to target and treat skin conditions, offering effective solutions for a wide range of dermatological concerns.
Dermatological agents encompass a diverse array of compounds, including corticosteroids, antifungal agents, antibacterials, retinoids, and immunomodulators. Each API within this category possesses unique properties and mechanisms of action, enabling them to address specific skin-related issues.
Corticosteroids, for instance, are potent anti-inflammatory agents commonly used in the treatment of skin conditions like eczema, psoriasis, and dermatitis. Antifungal agents, on the other hand, combat fungal infections such as athlete's foot or ringworm. Antibacterials are effective against bacterial infections, while retinoids promote skin cell turnover and treat acne and photoaging. Immunomodulators regulate the immune response, providing relief from conditions like atopic dermatitis.
The development and application of dermatological APIs involve rigorous research, clinical trials, and regulatory compliance. These APIs are typically integrated into topical creams, ointments, gels, and lotions, ensuring targeted delivery to the affected areas of the skin.
Dermatological agents play a crucial role in the management and treatment of various skin disorders. By harnessing the therapeutic properties of these APIs, pharmaceutical companies can develop innovative skincare products that cater to the diverse needs of individuals seeking effective dermatological solutions.
Desonide API manufacturers & distributors
Compare qualified Desonide API suppliers worldwide. We currently have 8 companies offering Desonide API, with manufacturing taking place in 6 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Cambrex | Producer | Italy | United States | CoA, GMP | 104 products |
| Farmabios | Producer | Italy | Italy | CoA, GMP, ISO9001, USDMF | 58 products |
| Gonane Pharma | Producer | India | India | BSE/TSE, CoA, GMP, MSDS | 166 products |
| Hunan Yuxin Pharmaceutica... | Producer | China | China | CoA, USDMF | 14 products |
| KRKA | Producer | Slovenia | Slovenia | CoA, GMP | 81 products |
| LGM Pharma | Distributor | United States | World | BSE/TSE, CEP, CoA, GMP, MSDS, USDMF | 441 products |
| Sicor | Producer | Italy | Italy | CoA, GMP | 47 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CoA, ISO9001, USDMF | 762 products |
When sending a request, specify which Desonide API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Desonide API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Desonide API
Sourcing
What matters most when sourcing GMP-grade Desonide?
Which documents are typically required when sourcing Desonide API?
Which manufacturers are known to produce Desonide API?
How can I request quotes for Desonide API from GMP suppliers?
Is a GMP audit report available for Desonide manufacturers?
How many suppliers offer Desonide API on Pharmaoffer?
Which countries are known to manufacture Desonide API?
Which certifications do suppliers of Desonide usually hold?
Technical
What is Desonide (CAS 638-94-8) used for?
Which therapeutic class does Desonide fall into?
What conditions is Desonide mainly prescribed for?
How does Desonide work?
What should someone know about the safety or toxicity profile of Desonide?
What are important formulation and handling considerations for Desonide as an API?
Is Desonide a small molecule?
Are there special stability concerns for oral Desonide?
Regulatory
Where is Desonide approved or in use globally?
What’s the regulatory and patent landscape for Desonide right now?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Desonide procurement?
Is Desonide included in the PRO Data Insights coverage?
Where can I access the API market report for Desonide?
